Chemi-Verse™ CDK9/CyclinT Kinase Assay Kit

Catalog #
82233
$1,550 *
Size: 384 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ CDK9/CyclinT Kinase Assay Kit is designed to measure CDK9 (cyclin dependent kinase 9)/Cyclin T kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 384-well format, with enough purified recombinant CDK9/Cyclin T kinase, kinase substrate, ATP, and kinase assay buffer for 400 enzyme reactions.

Synonyms
Cyclin-dependent kinase 9, C-2K, Cell division cycle 2-like protein kinase 4, Cell division protein kinase 9, Serine/threonine-protein kinase PITALRE, Tat-associated kinase complex catalytic subunit, CDC2L4, TAK, Cyclin-T1, CycT1, CCNT1, CDK-9
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator
Format
Catalog # Name Amount Storage
40307 CDK9/CyclinT, GST-Tag* 2 x 10 µg -80°C
79334 5x Kinase Buffer 1 2 x 1.5 ml -20°C
79686 500 µM ATP 200 µl -20°C
79604 5x CDK Substrate Peptide 2 2 x 1 ml -20°C
79969 White 384-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
CDK9: P50750; CyclinT1: O60563
Background

Cyclin-dependent kinase 9 (CDK9) is the catalytic subunit of the positive transcription elongation factor b (P-TEFb) complex, which phosphorylates the C-terminal domain of RNA polymerase II, a key player in the production of mature RNA. P-TEFb also includes cyclin T. CDK9 translocates to the nucleus once it gets auto phosphorylated, where it can associate with cyclin T. Hyperactivation of cyclins is known to result in cancer and the development of resistance to therapy, and CDK9-cyclin T is involved in the transcription of oncogenes. The inhibition or degradation of specific CDK-cyclin complexes could prove beneficial in cancer treatment, but the development of specific inhibitors has been difficult. Recently a small molecule degrader specific for CDK9-cyclin T was identified, LL-K9-3, which resulted in lower levels of androgen receptor (AR) and cMyc in 22RV1 cells. LL-K9-3 thus seemed more effective than SNS032, its parental CDK9 inhibitor, and the CDK9 PROTAC Thal-SNS032. Further research into new and more specific molecules will prove beneficial for cancer therapy.

References

Napolitano G, et al., 2003 J Cell Physiol. 197(1):1-7.
Li J., et al., 2022 J Med Chem. 65(16):11034-11057.